| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CFO
1 company
Christine Mikail Cvijic is President and CFO at NGNE. Christine Mikail Cvijic's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.2M at current prices.
Historically, Christine Mikail Cvijic's trades have earned a below-average insider score of 46/100 across 10 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -14.6%.
The NGNE filings lean toward selling, a net 11,104 shares.
Christine Mikail Cvijic has 10 Form 4 filings on record from March 2024 to July 2026, all as President and CFO at Neurogene (NGNE), 2024–2026.
The 18 reported transactions were 13 open-market sales, 2 stock awards, 2 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $491K and 7 sales worth about $976K.
The only open-market purchase was 24,000 shares of NGNE at an average $20.48 on November 22, 2024, about $491K. Twelve months later NGNE was down 1%.
The largest open-market sale was 9,600 shares of NGNE at an average $31.25 on May 6, 2026, about $300K.
All 7 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 4,800 | $36.12 | $173,375.40 | -5.4% | -28.1% | - | |
| Jul 2, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 4,800 | $34.71 | $166,586.36 | -5.1% | -21.3% | - | |
| May 6, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 9,600 | $31.25 | $300,043.20 | -9.3% | +6.4% | - | |
| Mar 26, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 2,558 | $21.62 | $55,315.98 | -2.4% | +40.4% | - | |
| Mar 13, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 4,045 | $20.81 | $84,176.31 | -3.7% | +34.8% | - | |
| Feb 27, 2026 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 4,800 | $25.11 | $120,526.08 | -4.2% | +17.1% | - | |
| Mar 13, 2025 | NGNE Neurogene Inc. | President and CFO | Sell10b5-1 | 4,501 | $16.94 | $76,246.94 | -5.9% | +24.5% | +28.0% | |
| Nov 22, 2024 | NGNE Neurogene Inc. | President and CFO | Buy | 24,000 | $20.48 | $491,400.00 | +45.4% | -14.7% | -1.2% |